FOLH1 and posterior cortical atrophy: Positron emission tomography targeting prostate-specific membrane antigen (PSMA-PET) has emerged in recent years as the reference standard examination not only for BCR recurrence but also for initial staging in patients with intermediate- and high-risk PCa according to the latest guidelines from the European Association of Urology (EAU) with better accuracy and fewer equivocal results as compared with conventional imaging modalities (CT and BS) [8,9,10,11,12].